Earnings call transcript: Ser Educacional Q1 2026 beats EPS, misses revenue

Ser Educacional delivered mixed Q1 2026 results: EPS of $0.5355 beat estimates by 4.82%, while revenue of $583.9 million missed consensus by 1.35%. Net income rose more than 70% year over year and net debt fell over 35% to its lowest level since 2021, but the shares declined 1.34% after hours to $12.51. Management reiterated 2026 expansion plans, including five new unit openings, while noting competitive pressure in medical school pricing and regulatory complexity in distance/hybrid learning.

Analysis

The key read-through is not the headline earnings beat; it is the re-pricing of the company’s mix. A higher share of revenue from on-campus and medical programs improves near-term margin durability, but it also concentrates the business into the most competitively contested, most regulation-sensitive pocket of Brazilian higher education. That means the next leg of upside depends less on demand growth and more on whether management can preserve ticket economics while adding capacity without diluting pricing power.

The second-order winner is the balance sheet. Rapid deleveraging creates optionality: lower interest expense can mechanically keep EPS growing even if top-line growth stays mid-single digits, and it gives management room to fund expansions and dividends at the same time. The market may be underestimating how quickly financial leverage can become a strategic weapon here — not just a cleanup story, but a way to outlast smaller operators that need to discount aggressively to fill seats.

The main risk is that current earnings quality is front-loaded. A mix of one-time pricing actions, accelerated collections, and temporary expense timing can make margins look more durable than they are over the next 2-3 quarters. If medical school pricing softens further or expansion units take longer to ramp, the stock can easily de-rate from a “cheap earnings” name into a “cheap but capped” name, especially if investors start discounting the sustainability of the current cash conversion.

Contrarian view: the post-earnings selloff may be too focused on the revenue miss and not enough on the capital structure reset. If management can execute five openings with mostly expansion-based CapEx, the equity can compound through 2026 even without a big acceleration in enrollments. The setup favors a patient long, but only if you’re underwriting normalized rather than peak-margin profitability.

Key Decisions for Investors

• Long SEER3 on weakness over the next 2-6 weeks: attractive if the stock stays below the post-earnings reaction level; use a 12-month horizon and size for a 15-25% upside / 8-10% downside profile if deleveraging and dividend resumption persist.
• Pair trade: long SEER3 / short a lower-quality Brazil education operator for 3-6 months, betting that balance-sheet strength and higher mix will outperform in a slower demand environment.
• Buy a modest call spread in SEER3 for the next 6-9 months rather than outright stock if you want exposure to expansion upside while limiting risk that medical pricing normalizes faster than expected.
• Fade the rally if SEER3 re-rates above a high-teens forward multiple without evidence of stable medical ticket trends; that would price in margin expansion that may not be repeatable.
• Monitor for a 1-2 quarter lag in expansion CapEx and any deterioration in discounting behavior; if early unit ramp is weak, reduce long exposure before the market revises 2026 EBITDA estimates.